Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Return on Equity (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Return on Equity data on record, last reported at 0.02% in Q3 2025.

  • For Q3 2025, Return on Equity rose 170.0% year-over-year to 0.02%; the TTM value through Sep 2025 reached 0.02%, up 170.0%, while the annual FY2023 figure was 0.49%, N/A changed from the prior year.
  • Return on Equity reached 0.02% in Q3 2025 per CRVS's latest filing, up from 0.48% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.02% in Q3 2025 and bottomed at 2.19% in Q4 2024.
  • Average Return on Equity over 4 years is 0.74%, with a median of 0.57% recorded in 2022.
  • Peak YoY movement for Return on Equity: tumbled -165bps in 2024, then surged 170bps in 2025.
  • A 4-year view of Return on Equity shows it stood at 0.54% in 2022, then rose by 1bps to 0.53% in 2023, then tumbled by -309bps to 2.19% in 2024, then soared by 99bps to 0.02% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.02% in Q3 2025, 0.48% in Q2 2025, and 0.67% in Q1 2025.